Literature DB >> 4853286

Multiple dose kinetics of spironolactone and canrenoate-potassium in cardiac and hepatic failure.

W Sadée, R Schröder, E von Leitner, M Dagcioglu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4853286     DOI： 10.1007/bf00560381

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  14 in total

1.  Spironolactone--a weak enzyme inducer in man.

Authors:  S A Taylor; M D Rawlins; S E Smith
Journal:  J Pharm Pharmacol       Date:  1972-07       Impact factor: 3.765

2.  Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans.

Authors:  W Sadée; M Dagcioglu; R Schröder
Journal:  J Pharmacol Exp Ther       Date:  1973-06       Impact factor: 4.030

3.  Fluorometric microassay for spironolactone and its metabolites in biological fluids.

Authors:  W Sadée; M Dagcioglu; S Riegelman
Journal:  J Pharm Sci       Date:  1972-07       Impact factor: 3.534

4.  The effect of spironolactone on drug metabolism by hepatic microsomes.

Authors:  B Stripp; M E Hamrick; N G Zampaglione; J R Gillette
Journal:  J Pharmacol Exp Ther       Date:  1971-03       Impact factor: 4.030

5.  [Positive-inotropic heart effect of aldadiene-potassium (Aldactone pro injections)].

Authors:  R Schröder; K P Schüren; G Biamino; V Meyer; W Sadée
Journal:  Klin Wochenschr       Date:  1971-10-01

6.  The influence of spironolactone on its own biotransformation.

Authors:  B Solymoss; S Tóth; S Varga; M Krajny
Journal:  Steroids       Date:  1970-09       Impact factor: 2.668

7.  A fluorimetric method for the determination of a major spironolactone (Aldactone) metabolite in human plasma.

Authors:  N GOCHMAN; C L GANTT
Journal:  J Pharmacol Exp Ther       Date:  1962-03       Impact factor: 4.030

8.  Isolation and identification of novel sulfur-containing metabolites of spironolactone (Aldactone).

Authors:  A Karim; E A Brown
Journal:  Steroids       Date:  1972-07       Impact factor: 2.668

9.  A comparison of the use of Aldactone and Aldactone A in the treatment of hepatic ascites.

Authors:  S SHALDON; J A RYDER; M GARSENSTEIN
Journal:  Gut       Date:  1963-03       Impact factor: 23.059

10.  [Direct positive inotropic cardiac effect of aldactone (spironolactone, canrenoate-K)].

Authors:  R Schröder; B Ramdohr; U Hüttemann; K P Schüren
Journal:  Dtsch Med Wochenschr       Date:  1972-10-13       Impact factor: 0.628
View more
  18 in total

Review 1.  Critical compilation of terminal half-lives, percent excreted unchanged, and changes of half-life in renal and hepatic dysfunction for studies in humans with references.

Authors:  L A Pagliaro; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1975-10

2.  The pharmacokinetics of trilostane and ketotrilostane in an interconverting system in the rat.

Authors:  J P McGee; P N Shaw
Journal:  Pharm Res       Date:  1992-04       Impact factor: 4.200

3.  Bioassay of aldosterone antagonists in normal human subjects: a relationship between the level of plasma uric acid before treatment and apparent drug responses.

Authors:  L E Ramsay; P Hessian; M J Tidd
Journal:  Br J Clin Pharmacol       Date:  1975-06       Impact factor: 4.335

4.  Effects of pretreatment with spironolactone of pharmacokinetics of 4'''-methyldigoxin in man.

Authors:  U Abshagen; H Rennekamp; J Kuhlmann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1976       Impact factor: 3.000

5.  Canrenone--the principal active metabolite of spironolactone?

Authors:  L E Ramsay; J R Shelton; D Wilkinson; M J Tidd
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

6.  Comparison of plasma levels of canrenone and metabolites after base hydrolysis in young and elderly subjects following single and multiple doses of spironolactone.

Authors:  P C Ho; D W Bourne; E J Triggs; B A Smithurst
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

7.  Comparison of prorenoate potassium and spironolactone after repeated doses and steady state plasma levels of active metabolites.

Authors:  G T McInnes; J R Shelton; I R Harrison; R M Perkins; R F Palmer
Journal:  Br J Clin Pharmacol       Date:  1982-02       Impact factor: 4.335

Review 8.  Clinical pharmacokinetics of diuretics.

Authors:  B Beermann; M Groschinsky-Grind
Journal:  Clin Pharmacokinet       Date:  1980 May-Jun       Impact factor: 6.447

9.  Spironolactone dose-response relationships in healthy subjects.

Authors:  G T McInnes; R M Perkins; J R Shelton; I R Harrison
Journal:  Br J Clin Pharmacol       Date:  1982-04       Impact factor: 4.335

10.  The pharmacodynamics of single doses of prorenoate potasssium and spironolactone in fludrocortisone treated normal subjects.

Authors:  L E Ramsay; J R Shelton; M J Tidd
Journal:  Br J Clin Pharmacol       Date:  1976-06       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.